最近在重新塑造NSAID及其衍生物作为抗癌候选药物的进展
Asmaa E Kassab1, Ehab M Gedawy1,2
1Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, P.O. Box 11562, Egypt.
非类固醇抗炎药物 (NSAIDs) 通过向炎症,在癌症治疗中表现有前途. 重用NSAID为开发新的抗癌药物提供了更快,更便宜的途径.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 药物重用 药物重用
背景情况:
- 炎症是瘤发育和癌症进展的关键因素.
- 非类固醇抗炎药物 (NSAIDs) 可以改变瘤微环境,增强细胞亡和化学敏感性,同时减少细胞迁移.
- 药物重定向正在获得引力,作为开发新癌症疗法的成本效益和时间效率高的战略.
研究的目的:
- 审查NSAID衍生物对抗癌症的抗增殖活性.
- 探索这些NSAIDs的作用机制和结构-活性关系 (SARs).
- 评估在临床癌症治疗中重新使用NSAID的潜力.
主要方法:
- 2017年至2023年间发表的研究文献综述.
- 分析特定的NSAID衍生物 (迪克洛菲纳克,埃托多拉克,塞莱科西布,布洛芬,托尔梅丁,苏林达克) 的抗增殖作用.
- 对作用机制和SARs的检查.
主要成果:
- 无 NSAID衍生品表现出与癌症治疗相关的显著抗增殖活性.
- 特定的NSAID显示出可能有利地改变瘤微环境的潜力.
- 了解SARs为设计更有效的NSAID基于癌症治疗提供了基础.
结论:
- 无抗炎药物及其衍生物是癌症预防和治疗的一类有前途的化合物.
- 对NSAIDs的药物重新定位为加速开发新型抗癌药物的可行策略.
- 对NSAID机制和SAR的进一步研究可以指导瘤学中的临床应用.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Prevention
Some...
Inhibition of Cdk Activity
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
